Oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal strategy: A French multicentric study
Cancer/Radiothérapie · 2024
DOI: 10.1016/j.canrad.2024.05.005 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer/Radiothérapie, 2024. Verfasst von Carolinne Brassart und 8 weiteren Autor:innen. Beteiligte Einrichtung: Academic Department of Radiation Oncology, centre Oscar-Lambret, 3, rue Frédéric-Combemale, 59000 Lille, France. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Neoplasm Invasiveness. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Trimodal therapy, an organ-sparing alternative, may be proposed for selected patients with muscle-invasive bladder cancer instead of radical cystectomy. In this multicentre retrospective study, we aimed to assess the oncological outcomes of patients who had trimodal therapy for a muscle-invasive bladder cancer. MATERIALS AND METHODS: Seventy-three patients from four centres treated who had trimodal therapy (maximal transurethral resection of bladder tumour and concomitant chemoradiotherapy) for localized muscle-invasive bladder cancer were included. Patients meeting the optimal trimodal therapy eligibility criteria as per the European Association of Urology guidelines were identified. Overall survival, recurrence-free survival and cancer-specific survival were assessed using the Kaplan-Meier method. The cumulative incidence of recurrence was estimated using the Kalbfleisch-Prentice method. RESULTS: Median overall survival was 27.0 months (95 % confidence interval [CI]: 20.3-58.3 months), 5-years overall-, cancer-specific- and recurrence-free survival rates were 37.5% (95 % CI: 25.5-49.5 %), 60 % (95 % CI: 48.3-72.0 %), and 17.9 % (95 % CI: 9.3-28.8 %), respectively. There was no significant difference in 5-year overall survival and recurrence-free survival between the trimodal therapy-eligible and non-eligible patients (hazard ratio [HR]: 1.38, P=0.30 and HR: 0.96, P=0.90, respectively). The univariate analysis did not reveal any significant prognostic factors associated with recurrence-free or overall survival. CONCLUSION: Trimodal therapy offers encouraging specific survival, the prognosis remains poor. Our study highlights the low number and high frailty of patients to whom trimodal therapy is offered in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Academic Department of Radiation Oncology, centre Oscar-Lambret, 3, rue Frédéric-Combemale, 59000 Lille, France.
- Academic Department of Radiation Oncology, CHU d'Amiens, 1, rue du Professeur-Christian-Cabrol, 80000 Amiens, France.
- Methodology and Biostatistics unit, centre Oscar-Lambret, Lille, France.
- Department of Radiation Oncology, centre François-Baclesse, 3, avenue du Général-Harris, 14000, Caen, France.
- Academic Department of Radiation Oncology, centre Henri-Becquerel, 1, rue d'Amiens, 76038 Rouen, France.
- Academic Department of Radiation Oncology, centre Oscar-Lambret, 3, rue Frédéric-Combemale, 59000 Lille, France; Centre de recherche en informatique, signal et automatique de Lille, Cristal UMR 9189, université de Lille…
Zitieren
APA
Brassart, C., Coutte, A., Wallet, J., Meyer, E., Benyoucef, A., Mnif, H., Kowalski, V., Barthoulot, M., & Pasquier, D. (2024). Oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal strategy: A French multicentric study. Cancer/Radiothérapie. https://doi.org/10.1016/j.canrad.2024.05.005
Vancouver
Brassart C, Coutte A, Wallet J, Meyer E, Benyoucef A, Mnif H, et al. Oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal strategy: A French multicentric study. Cancer/Radiothérapie. 2024. doi:10.1016/j.canrad.2024.05.005
BibTeX
@article{Brassart2024,
author = {Brassart, Carolinne and Coutte, Alexandre and Wallet, Jennifer and Meyer, Emmanuel and Benyoucef, Ahmed and Mnif, Hajer and Kowalski, Vincent and Barthoulot, Maël and Pasquier, David},
title = {Oncological outcomes of patients with muscle-invasive bladder cancer treated with trimodal strategy: A French multicentric study},
journal = {Cancer/Radiothérapie},
year = {2024},
doi = {10.1016/j.canrad.2024.05.005}
}
EUVIMED